KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Interest & Investment Income (2016 - 2025)

West Pharmaceutical Services' Interest & Investment Income history spans 17 years, with the latest figure at $5.1 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 6.25% year-over-year to $5.1 million; the TTM value through Dec 2025 reached $17.5 million, down 10.71%, while the annual FY2025 figure was $17.5 million, 10.71% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $5.1 million at West Pharmaceutical Services, up from $4.7 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $9.4 million in Q4 2023 and bottomed at $100000.0 in Q1 2021.
  • The 5-year median for Interest & Investment Income is $4.0 million (2024), against an average of $3.6 million.
  • The largest annual shift saw Interest & Investment Income plummeted 87.5% in 2021 before it surged 1500.0% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $300000.0 in 2021, then soared by 866.67% to $2.9 million in 2022, then surged by 224.14% to $9.4 million in 2023, then tumbled by 48.94% to $4.8 million in 2024, then grew by 6.25% to $5.1 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Interest & Investment Income are $5.1 million (Q4 2025), $4.7 million (Q3 2025), and $3.6 million (Q2 2025).